Jm. Coulson et al., E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer, BIOCHEM J, 344, 1999, pp. 961-970
[Arginine]vasopressin (AVP) is a neuropeptide physiologically synthesized i
n the hypothalamus but pathologically expressed by small-cell lung cancer (
SCLC). A minimal 65 bp AVP promoter can restrict basal activity to SCLC in
vitro, but a 199 bp fragment directs 5-fold higher expression in SCLC [Coul
son, Stanley and Well (1999) Br. J. Cancer 80, 1935-1944]. Several predicte
d E-box motifs occur within the 199 bp fragment, and we now describe an enh
ancer which contributes to AVP promoter tumour-specificity in some cell lin
es. The deletion of two adjacent E-boxes (-157 to -131) resulted in an appr
ox. 70% loss of reporter gene expression in a SCLC line (Lu-165) with high
endogenous AVP production. Using a series of AVP promoter deletion construc
ts and site-directed mutagenesis, we show that both these E-box sites were
required for enhancer function, whereas mutation of an adjacent AP-1 site h
ad no effect on the promoter activity. Electrophoretic-mobility-shift analy
sis indicated that, although both the predicted E-box motifs bound specific
complexes, only one appeared to function as a strong E-box which binds bas
ic helix-loop-helix (bHLH) factors. This motif formed a complex in lung tum
our-cell extracts, which was particularly strongly bound in Lu-165, and was
competed for by a characterized E-box motif from the preprotachykinin A pr
omoter. Antibody supershifts indicate that this complex is a heterodimer of
upstream stimulatory factor (USF)-1 and USF-2. Non-bHLH complexes weakly b
ound the second potential E-box motif in a SCLC-specific manner. These comp
lexes were not recognized by the bHLH antibodies and remain unidentified; h
owever, they were detected in seven of eight SCLC cell lines and not in fou
r control lines. We postulate that there is a co-operative and complex inte
raction between an E-box and an adjacent site constituting a SCLC-specific
enhancer within the AVP proximal promoter.